At the Outsourcing in Clinical Trials East Coast 2025 conference in King of Prussia, panelists were asked how trial sponsors ...

Ionis Pharmaceuticals has reported outcomes from the Phase III Essence study of olezarsen in individuals with moderate ...

The FDA in the US has granted clearance to BrainStorm to commence a Phase IIIb trial of its NurOwn therapy for ALS.

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial of ifinatamab ...

The progress the UK has made as a global contributor to clinical trials is “remarkable”, says former health minister Lord ...

The theme for International Clinical Trials Day 2025, set by the Association of Clinical Research Professionals is “Powered by Purpose”.

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01.

Sarepta Therapeutics has announced new outcomes from its Phase Ib Study 9001-103, named Endeavour, of Elevidys for DMD.

Neurogene said it would conduct daily monitoring for the ‘three Fs’ in the week after dosing with the gene therapy.